Form 4: Phathom Pharmaceuticals Director Acquires Shares

Michael F. Cola, a Director at Phathom Pharmaceuticals, Inc., acquired 24,122 shares of common stock through Restricted Stock Units (RSUs) granted on May 19, 2026.

Summary

• Michael F. Cola, a Director of Phathom Pharmaceuticals, Inc., acquired 24,122 shares of common stock.
• The acquisition occurred on May 19, 2026, through the grant of Restricted Stock Units (RSUs) under the Issuer's Non-Employee Director Compensation Program.
• These RSUs vest on the first anniversary of the grant date or the next annual stockholder meeting, provided the director remains in service.
• Each RSU represents a contingent right to receive one share of common stock.
• Following this transaction, Mr. Cola beneficially owns 63,920 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard director compensation grant rather than a significant insider purchase or sale that might indicate a strong market signal.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The grant of RSUs aligns director compensation with long-term shareholder value through vesting conditions tied to service and time.

Future Outlook

The RSUs are subject to vesting conditions, with 100% vesting on the first anniversary of the grant date or the next annual stockholder meeting, contingent on the Reporting Person's continued service.

Industry Context

StockSavvy.ai notes that director share grants are a common practice in the biopharmaceutical industry to incentivize leadership and align their interests with those of shareholders, particularly during periods of development and potential growth.

Stakeholder Impact

• Shareholders: The acquisition through RSUs is a standard compensation mechanism and does not immediately impact share price, but aligns director interests with long-term shareholder value.
• Employees: The compensation structure for directors is separate from employee compensation.
• Management: The transaction is part of the established director compensation program.

Next Steps

• Vesting of RSUs on the first anniversary of the grant date or the next annual stockholder meeting, subject to continued service.
• Potential future sale of vested shares by the reporting person.

Key Dates

Keywords

Phathom Pharmaceuticals, PHAT, Form 4, Director Compensation, Restricted Stock Units, RSUs, Share Acquisition, Beneficial Ownership